Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a Phase 2 clinical-stage biopharmaceutical company focused on personalized oncology through the development of stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor, and its proprietary DRP® companion diagnostic platform. The Allarity news feed highlights how the company advances this program in advanced ovarian cancer and other hard-to-treat malignancies.
News updates commonly cover clinical trial milestones, such as enrollment progress and new Phase 2 data in platinum-resistant or platinum-ineligible ovarian cancer, including Kaplan–Meier analyses of overall survival and durability of response. Releases also report on regulatory developments, notably the FDA Fast Track designation granted to stenoparib for advanced ovarian cancer, and on scientific presentations at meetings like the AACR Special Conference on Ovarian Cancer and Biomarkers & Precision Medicine.
Investors and observers will find coverage of corporate and financial updates, including quarterly results, capital structure actions, and private placement transactions disclosed via Form 8-K. Additional news items describe the expansion of Allarity’s DRP® platform through licensing and laboratory services agreements with EU-based biotechnology partners, patent developments such as Australian acceptance for the stenoparib DRP®, and collaborations with institutions like the Indiana Biosciences Research Institute.
This page aggregates these announcements so readers can follow how Allarity is progressing stenoparib in ovarian cancer, preparing combination studies in recurrent small cell lung cancer, and broadening the use of its DRP® technology across oncology. For ongoing insight into trial data, regulatory interactions, intellectual property, and financing events related to ALLR, this curated news stream provides a centralized view.
Allarity Therapeutics reported financial results for Q4 and full year 2021, highlighting significant achievements including a successful Nasdaq listing under symbol ALLR and a record investment of $20 million. The company advanced its cancer therapeutics pipeline and announced a forbearance agreement to address compliance issues with Nasdaq. Notably, R&D expenses surged to $14.2 million, leading to a net loss of $26.6 million for 2021. Positive developments include a Type C meeting with the FDA on dovitinib and milestone payments from partnerships. Cash reserves increased to $19.6 million.
Allarity Therapeutics, Inc. (Nasdaq: ALLR) announced it is not in compliance with Nasdaq Listing Rule 5250(c)(1), due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The notification does not immediately affect the listing of the Company's common stock. Allarity has 60 days to submit a compliance plan, with a potential extension of up to 180 days if accepted. The Company aims to file its Form 10-K by June 19, 2022, to eliminate the need for a formal compliance plan.
Allarity Therapeutics has requested a Type C meeting with the FDA to discuss the next steps for dovitinib, after the agency issued Refusal to File letters for its NDA and PMA applications. The Company aims to clarify the requirements for resubmission and anticipates a new clinical trial may be necessary. Allarity plans to provide updates on the meeting outcomes and further advancements for dovitinib and its DRP-Dovitinib companion diagnostic by the end of Q3 2022. CEO Steve Carchedi remains confident in dovitinib's potential as a treatment for cancer patients.
Allarity Therapeutics, Inc. announced that the FDA issued Refusal to File letters for their new drug application (NDA) for dovitinib and the companion diagnostic DRP®-Dovitinib. The FDA cited insufficient clinical trial data to conclude efficacy for the metastatic renal cell carcinoma treatment. Allarity plans to seek FDA guidance and likely conduct a new clinical trial to address the issues raised. Despite this setback, Allarity's CEO remains confident in dovitinib's potential as a treatment option.
Allarity Therapeutics (Nasdaq: ALLR) has entered into licensing agreements with Oncoheroes Biosciences for the development of dovitinib and stenoparib in pediatric cancers. Oncoheroes will fund and advance clinical trials, while Allarity will provide support and supply drug inventory. Allarity submitted a new drug application (NDA) for dovitinib in renal cell carcinoma (RCC), alongside the Dovitinib-DRP® companion diagnostic. The company is also evaluating stenoparib for advanced ovarian cancer. Financial terms of the agreements remain undisclosed.